SUNNYVALE, California and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ --
New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation
Therapy Approach in the Treatment of Oligometastases
Accuray Incorporated and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife(R) System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. The trial brings the hospital one step closer to its goal of providing individual, personalized medicine.
"At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC. "We initiated this trial because we want to improve local cancer control and minimize toxicities in people with pelvic or intra-abdominal oligometastases."
Oligometastastic disease occurs when cancer cells from the primary tumor travel to other parts of the body and form a small number (less than six) of lesions. The cancerous cells are in an intermediate state; they are no longer confined to their initial location nor have they spread widely throughout the body. Radiation treatment of oligometastatic disease in the pelvic or intra-abdominal area is challenging because of the close proximity of healthy organs very sensitive to radiation. From one day to the next there can be a significant variation in the position of these organs and it can be difficult to account for the changes in their location on a daily basis.
To address this issue, Accuray and Erasmus MC are partnering to develop an integrated, advanced, imaging solution tailored for use with the CyberKnife System. The purpose is to enable clinicians to adapt the treatment plan to daily anatomical changes within the patient. According to Dr. Nuyttens, "This OA-SBRT strategy provided the treated patient with an optimal combination of dose to the tumor and sparing of the surrounding healthy organs."
"We are thrilled to have the opportunity to collaborate with Erasmus MC on the first step of a longer-term CyberKnife initiative to enhance the quality of care clinicians can offer to their patients," said Fabienne Hirigoyenberry-Lanson, PhD, Vice President Global Medical and Scientific Affairs at Accuray. "We believe a system that provides clinicians with the ability to tailor the treatment on a daily basis through a fully automated solution, and track and automatically correct for tumor or patient movement throughout the treatment, has the potential to create a paradigm shift in the way radiation is delivered and in cancer care."
About the Study This study is a non-randomized single arm phase II clinical trial evaluating the use of OA-SBRT for the treatment of oligometastatic disease in the pelvic or paraaortic region. In total, 53 patients will be enrolled and will be followed for three years. A prescription dose of 45 Gy will be delivered in five fractions by the CyberKnife System. The primary study objectives are to evaluate local control, survival and toxicity.
Important Safety Information For Important Safety Information please refer to http://www.accuray.com/safety-statement.
About Erasmus MC Cancer Institute Erasmus MC is committed to a healthy population and excellence in healthcare through research and education. Professionals who are trained by Erasmus MC unite the latest scientific insights with practical application, so that patients and people with a healthcare need can benefit fully from this link. Innovation and state-of-the-art treatment go hand-in-hand at Erasmus MC.
About Accuray Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com or follow us on Facebook [https://www.facebook.com/AccurayIncorporated ], LinkedIn [https://www.linkedin.com/company/accuray ], Twitter [https://twitter.com/accuray ] and YouTube [https://www.youtube.com/user/AccurayIncorporated ].
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to develop new products or enhance existing products to meet customers' needs, the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report on Form 10-Q, filed with the SEC on February 5, 2018 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
CONTACT: Sancie Nakarat, Accuray, Tel: +33-681-368-434, E-Mail: email@example.com